Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists

被引：17
|
作者：
Mann, Johannes F. E. [1 ,2 ]
Muskiet, Marcel H. A. [3 ]
机构：
[1] KfH Kidney Ctr, 15 Isoldenst, D-80804 Munich, Germany
[2] Friedrich Alexander Univ, Univ Hosp, Dept Nephrol & Hypertens, Erlangen, Germany
[3] Vrije Univ, Amsterdam Univ, Med Ctr, Dept Internal Med,Diabet Ctr, Amsterdam, Netherlands
来源：
KIDNEY INTERNATIONAL | 2021年 / 99卷 / 02期
关键词：
RENAL OUTCOMES; CARDIOVASCULAR OUTCOMES; LIRAGLUTIDE;
D O I：
10.1016/j.kint.2020.08.036
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：314 / 318
页数：5
相关论文
共 50 条
  • [31] GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?
    Brunton, S.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2014, 68 (05) : 557 - 567
  • [32] The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors
    Secrest, Matthew H.
    Udell, Jacob A.
    Filion, Kristian B.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2017, 27 (03) : 194 - 202
  • [33] Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes? The time has come for GLP-1 receptor agonists!
    Schwartz, Stanley
    DeFronzo, Ralph A.
    DIABETES CARE, 2013, 36 (07) : 2107 - 2111
  • [34] Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
    Aroda, Vanita R.
    Henry, Robert R.
    Han, Jenny
    Huang, Wenying
    DeYoung, Mary Beth
    Darsow, Tamara
    Hoogwerf, Byron J.
    CLINICAL THERAPEUTICS, 2012, 34 (06) : 1247 - 1258
  • [35] Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors
    Neumiller, Joshua J.
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2009, 49 : S16 - S29
  • [36] From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy
    Dicembrini, Ilaria
    Pala, Laura
    Rotella, Carlo Maria
    EXPERIMENTAL DIABETES RESEARCH, 2011,
  • [37] SGLT2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors and Risk of All-Cause Hospitalization
    Lyu, Beini
    Grams, Morgan
    Chang, Alex R.
    Inker, Lesley A.
    Coresh, Josef
    Shin, Jung-Im
    DIABETES, 2021, 70
  • [38] Defining the Role of GLP-1 in the Enteroinsulinar Axis in Type 2 Diabetes Using DPP-4 Inhibition and GLP-1 Receptor Blockade
    Aulinger, Benedikt A.
    Bedorf, Anne
    Kutscherauer, Gabriele
    de Heer, Jocelyn
    Holst, Jens J.
    Goeke, Burkhard
    Schirra, Joerg
    DIABETES, 2014, 63 (03) : 1079 - 1092
  • [39] Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors
    Donna Shu-Han Lin
    Jen-Kuang Lee
    Wen-Jone Chen
    Diabetologia, 2021, 64 : 1949 - 1962
  • [40] Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors
    Lin, Donna Shu-Han
    Lee, Jen-Kuang
    Chen, Wen-Jone
    DIABETOLOGIA, 2021, 64 (09) : 1949 - 1962
12345